RBCC: n3D Technology Advances Cell Research

NOKOMIS, Fla.--(BUSINESS WIRE)--

Rainbow Biosciences, the biotech subsidiary of Rainbow Coral Corp. (RBCC), announced today that 3D cell culturing technology developed by its joint venture partner Nano3D BioSciences (n3D) was recently used in a breakthrough study using stem cells.

Dr. Mikhail Kolonin, an associate professor at the University of Texas Health Science Center at Houston, and Dr. Glauco Souza of n3D authored a study that demonstrates how effective 3D cell culturing by magnetic levitation is in generating white adipose tissue organoids, or adiposphere. In a significant breakthrough, these 3D structures presented vascular-like structures when pre-adpocyte stem cells were co-cultured with endothelial cells.

The study, Adipose tissue engineering in three-dimensional levitation tissue culture system based on magnetic nanoparticles, was published in the journal Tissue Engineering C.

This paper shows just how valuable n3Ds Bio-Assembler can be in ground-breaking research being conducted around the world, said RBCC CEO Patrick Brown. As more and more high-profile cell researchers discover this systems potential, the market for the technology will continue to grow exponentially.

The Bio-Assemblers fusion of magnetic levitation and nanoparticle assembly technology allows it to produce accurate, 3D representations of in vivo tissues faster and easier than any other existing tools. The incredible device is key to RBCCs plans to participate in the impressive upside in store for n3D.

For more information on Rainbow BioSciences, please visit http://www.rainbowbiosciences.com/investors.html.

Rainbow BioSciences will develop new medical and research technology innovations to compete alongside companies such as Bristol Myers Squibb Co. (NYSE:BMY),Biogen Idec Inc. (NASDAQ:BIIB), Abbott Laboratories (NYSE:ABT) and Amgen, Inc. (NASDAQ:AMGN).

About Rainbow BioSciences

Rainbow BioSciences, LLC, is a wholly owned subsidiary of Rainbow Coral Corp. (OTCBB:RBCC). The company continually seeks out new partnerships with biotechnology developers to deliver profitable new medical technologies and innovations. For more information on our growth-oriented business initiatives, please visit our website at [www.RainbowBioSciences.com]. For investment information and performance data on the company, please visit http://www.RainbowBioSciences.com/investors.html.

The rest is here:
RBCC: n3D Technology Advances Cell Research